Press Release

More Studies are Needed After FDA Issues Warning about Bisphosphonates Therapy

On October 13, the Food and Drug Administration published a warning to doctors and patients about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs called bisphosphonates. This warning was much awaited in the light of a report published in the American Journal of Bone and Mineral Research in September titled “Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research”

October 19, 2010 — On October 13, the Food and Drug Administration published a warning to doctors and patients about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs called bisphosphonates. This warning was much awaited in light of a report published in the American Journal of Bone and Mineral Research in September titled “Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research.”

fotolia_2150265_s

The ASBMR had assembled a special task force in March 2010 to make recommendations following a growing number of cases submitted to the FDA associating atypical fractures with prolonged use of bisphosphonates. The task force examined all published and unpublished data together with FDA data, and collected direct information from pharmaceutical industries selling the products. The FDA had reported in March that it would await the publication and recommendations from the ASBMR task force before enforcing any changes.

“The occurrences of atypical fractures using bisphosphonates have been known since 2007,” said Amar Sethi, MD, PhD, VP of Science and Technology at Pacific Biomarkers, a Seattle-based provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries. Dr. Sethi noted that a major study published in the New England Journal of Medicine earlier this year performed secondary analyses of three large, randomized bisphosphonate trials totaling more than 14,000 patients to explore this issue. The authors examined radiographs where available, and fracture records calculating hazard ratios for each study.

However, that study was not able to report any increase in  frequency of atypical fractures. The fact that only a small number of patients used bisphosphonates for more than 4.5 years may have decreased the power of the study to detect any association. Also, radiographs with the characteristics of atypical fractures were not available from all patients, raising questions about the classification accuracy of atypical fractures. Additional risk factors such as glucocorticoid use, rheumatoid arthritis, and low level of serum 25-hydroxyvitamin D may have confounded the study. “More studies are needed to explore the potential effects of these additional risk factors and to address the main question of bisphosphonates and fracture risk,” Dr. Sethi added.

Although the report from ASBMR acknowledges the association between atypical fractures and bisphosphonates, it stresses that this is a very uncommon phenomenon— observed in less than 1% of fractures—and that the benefits of therapy far outweigh its potential risks. Dr. Markus Seibel from the University of Sydney reinforced this during his presentation at the ASBMR’s 2010 meeting.

“The FDA warning is a direct consequence of ASBMR wanting to increase awareness of the warning signs associated with a potential fracture, namely groin and thigh pain lasting weeks,” noted Dr. Sethi. The ASBMR task force, he said, has therefore recommended changing the product labeling to improve the identification and tracking of atypical fractures associated with bisphosphonates use; to increase research toward the mechanistic explanation behind atypical fractures; and finally, among other recommendations, to perform retrospective analysis of bone turnover marker data in fracture patients before and after therapy to detect any suppression of bone turnover that may have occurred and possibly could explain the observed atypical fractures.

About Pacific Biomarkers, Inc.
Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, cell-based assays, mass spectrometry, and multiplex testing.
PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC”. For more information about PBI, visit the company’s website at www.pacbio.com.

Forward-Looking Statements
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company’s biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2009).

Contact
Pacific Biomarkers, Inc.
Ron Helm, CEO
(206) 298-0068

The Investor Relations Group
Janet Vasquez
(212) 825-3210

Pacific Biomarkers:
The Value of Expertise

Download PDF

Pacific Biomarkers:
The Value of Science

Download PDF

Pacific Biomarkers:
The Value of Client Team

Download PDF

Strategic Alliances

Download PDF